Hidekazu Kuramochi1, Takeshi Yamada2, Yoichiro Yoshida3, Akihisa Matsuda4, Hirohiko Kamiyama5, Chihiro Kosugi6, Keiichiro Ishibashi7, Atsuko Fukazawa8, Keisuke Ihara9, Hiromichi Sonoda4, Kazuhiko Yoshimatsu10, Hiroshi Yoshida4, Suguru Hasegawa3, Kazuhiro Sakamoto5, Hideyuki Ishida7, Keiji Koda6. 1. Department of Chemotherapy, Tokyo Women's Medical University, Yachiyo Medical Center, Yachiyo, Japan. 2. Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan; y-tak@nms.ac.jp. 3. Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan. 4. Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan. 5. Department of Coloproctological Surgery, Juntendo University Faculty of Medicine, Tokyo, Japan. 6. Department of Surgery, Teikyo University Chiba Medical Center, Ichihara, Japan. 7. Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan. 8. Department of Gastroenterological Surgery, Iwata City Hospital, Iwata, Japan. 9. First Department of Surgery, Dokkyo Medical University, Mibu, Japan. 10. Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Japan.
Abstract
BACKGROUND/AIM: Our multicenter phase II TAS-CC3 study demonstrated favorable median progression-free survival (PFS) and overall survival (OS) of 32 metastatic colorectal cancer (mCRC) patients treated with TAS-102 + bevacizumab as 3rd-line treatment. PATIENTS AND METHODS: We investigated the predictive and prognostic values of pre-treatment blood inflammation-based scores, including the neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR) and lymphocyte-to-monocyte ratio (LMR) on disease-control (DC), PFS and OS by a post-hoc analysis. RESULTS: Receiver operating characteristic curve analyses of the 3 inflammation-based scores versus DC showed the best predictive performance for LMR, followed by NLR and PLR. The high-LMR group had a significantly higher DC rate than the low group (87.5 vs. 43.8%). The high-LMR group showed significantly longer survival than the low group (4.9 vs. 2.3 m for median PFS) (21.0 vs. 6.1 m for median OS). CONCLUSION: The pre-treatment LMR is a valid predictive and prognostic biomarker for mCRC patients undergoing TAS-102 and bevacizumab treatment.
BACKGROUND/AIM: Our multicenter phase II TAS-CC3 study demonstrated favorable median progression-free survival (PFS) and overall survival (OS) of 32 metastatic colorectal cancer (mCRC) patients treated with TAS-102 + bevacizumab as 3rd-line treatment. PATIENTS AND METHODS: We investigated the predictive and prognostic values of pre-treatment blood inflammation-based scores, including the neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR) and lymphocyte-to-monocyte ratio (LMR) on disease-control (DC), PFS and OS by a post-hoc analysis. RESULTS: Receiver operating characteristic curve analyses of the 3 inflammation-based scores versus DC showed the best predictive performance for LMR, followed by NLR and PLR. The high-LMR group had a significantly higher DC rate than the low group (87.5 vs. 43.8%). The high-LMR group showed significantly longer survival than the low group (4.9 vs. 2.3 m for median PFS) (21.0 vs. 6.1 m for median OS). CONCLUSION: The pre-treatment LMR is a valid predictive and prognostic biomarker for mCRC patients undergoing TAS-102 and bevacizumab treatment.
Authors: Nieves Martínez-Lago; Teresa Calleja Chucla; Beatriz Alonso De Castro; Rafael Varela Ponte; Cristina Reboredo Rendo; Martin Igor Gomez-Randulfe Rodriguez; Sofia Silva Diaz; Begoña Graña Suarez; Juan de la Cámara Gomez; Fernando Busto Fernández; María Mateos Salvador; Margarita Reboredo Lopez Journal: Sci Rep Date: 2022-08-26 Impact factor: 4.996